Enzo Biochem, Inc. (NYSE:ENZ) Short Interest Down 6.9% in June

Enzo Biochem, Inc. (NYSE:ENZ) was the target of a significant decline in short interest in the month of June. As of June 15th, there was short interest totalling 560,500 shares, a decline of 6.9% from the May 31st total of 602,300 shares. Approximately 1.6% of the company’s shares are sold short. Based on an average daily volume of 114,700 shares, the short-interest ratio is presently 4.9 days.

Institutional Trading of Enzo Biochem

An institutional investor recently bought a new position in Enzo Biochem stock. FNY Investment Advisers LLC acquired a new position in Enzo Biochem, Inc. (NYSE:ENZ) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 75,911 shares of the medical research company’s stock, valued at approximately $105,000. FNY Investment Advisers LLC owned approximately 0.15% of Enzo Biochem as of its most recent SEC filing. Institutional investors own 36.90% of the company’s stock.

Enzo Biochem Price Performance

Shares of ENZ stock traded down $0.04 on Wednesday, hitting $1.03. The stock had a trading volume of 106,851 shares, compared to its average volume of 109,858. The company has a fifty day moving average price of $1.10 and a two-hundred day moving average price of $1.23. Enzo Biochem has a twelve month low of $0.99 and a twelve month high of $1.87.

Enzo Biochem Company Profile

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.